Al­terome rais­es $132M to take next-gen can­cer drugs aimed at the 'un­drug­gable' in­to clin­ic

With a new $132 mil­lion in hand, Al­terome Ther­a­peu­tics is fi­nal­ly di­vulging what it’s work­ing on.

The on­col­o­gy com­pa­ny will be us­ing its Se­ries B raise to bring two pro­grams — each de­signed to go af­ter spe­cif­ic can­cer-dri­ving mu­ta­tions — to the clin­ic with­in the next year. The San Diego start­up emerged from stealth in 2022, but had not dis­closed its pipeline un­til Wednes­day’s an­nounce­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER